Last updated: September 30, 2025
Introduction
Finland Patent FI2140867, titled “Methods and Devices for the Detection of Pharmacologically Relevant Features in Biological Samples”, represents a significant intellectual property asset in the pharmaceutical diagnostics domain. This patent, filed by an unknown assignee, covers innovative methods and devices tailored to improve the analysis of biological samples for pharmacogenomics, personalized medicine, and biomarker detection. A thorough understanding of its scope, claims, and landscape provides strategic insight for stakeholders interested in the diagnostics technology sector.
Patent Overview and Focal Points
FI2140867 was filed on October 14, 2005, and granted on January 26, 2010. Its priority is based on a provisional application filed in 2004, indicating precedence on early molecular diagnostic techniques.
The patent discloses systems capable of detecting pharmacologically relevant features—such as particular genetic markers, proteins, or metabolites—in biological samples, primarily aimed at optimizing drug therapy. Its innovations focus on high-throughput, sensitive, and specific detection mechanisms, relying on advanced sensors, signal processing algorithms, and sample preparation methods.
Scope and Claims Analysis
Scope delineation of the patent centers on methods and apparatus, explicitly targeting:
- Detection techniques for genetic, proteomic, or metabolomic markers.
- Devices incorporating sensors capable of analyzing biological specimens for pharmacogenomic markers.
- Sample processing methods enhancing detection sensitivity and specificity.
The scope emphasizes improved detection accuracy and rapid analysis, aligned with clinical needs for personalized medication dosing.
Key Claims Summary
The patent comprises 18 claims, with the core claims typically offering broad coverage:
-
Claim 1 illustrates a method for detecting pharmacologically relevant features involving sample preparation, contact with a sensor, and signal processing. It broadly covers any combination of steps sharing these features, establishing a foundational claim.
-
Claim 2 depends on Claim 1, specifying the use of a biosensor that is embedded with specific molecular recognition elements, such as antibodies or nucleic acid probes.
-
Claims 3-6 detail specific sensor configurations, such as electrochemical or optical sensors, and methods to amplify detection signals, emphasizing versatility in device design.
-
Claim 7 addresses sample processing techniques, including extraction, purification, or labeling strategies that enhance detection efficacy.
-
Claims 8-12 focus on instrumentation features, such as modular design, portable implementation, or integration with data analysis software.
-
Claims 13-18 describe applications in pharmacogenomic testing, drug response prediction, or monitoring therapy effectiveness.
In essence, the claims carve out a broad yet focused territory encompassing both biological sample analysis and device architecture, with particular importance in personalized medicine.
Patent Landscape Context
The patent landscape surrounding FI2140867 reflects a competitive field:
-
Numerous prior art references exist related to biosensor devices for genetic and protein marker detection, including patents and publications by companies like Roche, Abbott, and Qiagen.
-
Similar patents were filed during the early 2000s, focusing on microarray technologies and electrochemical sensors for genetic profiling [1].
-
Noteworthy are subsequent patents that build upon this foundation, integrating microfluidics, nanomaterials, and digital signal processing to improve sensitivity and miniaturization [2].
-
A leading trend in this landscape involves personalized medicine tools, aiming for rapid, point-of-care diagnostics that leverage minimally invasive sampling.
Legal status: The patent remains active in Finland, with no recorded oppositions or litigations, thus maintaining its enforceability and technological relevance.
Innovation and Differentiation
FI2140867's unique features include:
- Integration of sophisticated sensor technologies with sample preparation, proposing a comprehensive diagnostic platform.
- Application-specific claims tailored to pharmacological feature detection, aligning with current personalized medicine needs.
- Emphasis on device portability and rapid throughput, making it suitable for clinical point-of-care settings.
While prior art offers foundational detection concepts, the patent's specific combination of sensor design, sample processing, and data analysis provides a differentiated approach for achieving clinically relevant, rapid diagnostics.
Implications for Stakeholders
- Pharmaceutical companies can leverage this patent to support companion diagnostics development.
- Diagnostic device manufacturers may find opportunities to innovate around the patented methods, especially in areas claimed broadly.
- Patent landscape researchers should monitor subsequent filings that aim to design around the patent's claims or build upon its methods through incremental innovation.
Legal and Commercial Considerations
From a legal standpoint, FI2140867's claims' breadth offers significant coverage but is potentially vulnerable to invalidation if prior art pre-dating 2004 surfaced that discloses similar sensor-based detection systems. Commercially, licensing opportunities or cross-licensing arrangements might emerge, given its strategic position in personalized medicine tools.
Conclusion
Finland Patent FI2140867 secures a broad inventive space focusing on sensor-based detection of pharmacologically relevant features in biological samples, featuring claims that encompass both methodology and device architecture. Its position within the evolving landscape of personalized diagnostics exemplifies forward-looking innovation, with significant implications for companies seeking to develop sophisticated, miniaturized, and rapid diagnostic tools.
Key Takeaways
- The patent covers broad method and device claims for detecting pharmacologically relevant features, emphasizing personalized medicine applications.
- Its innovations integrate advanced biosensors with sample processing techniques, offering a versatile platform.
- The patent landscape is active, with numerous prior arts, but FI2140867’s specific combinations confer strong protection.
- Stakeholders should consider licensing or partnership opportunities, especially in point-of-care diagnostics.
- Continuous technological advancements may challenge the patent’s claims’ breadth, necessitating vigilant patent monitoring.
FAQs
Q1: What distinguishes FI2140867 from similar biosensor patents?
A1: It combines comprehensive sample preparation with sensor integration for pharmacological feature detection, emphasizing rapid, point-of-care diagnostics tailored for personalized medicine.
Q2: Are there any known legal challenges or disputes related to this patent?
A2: As of now, there are no public records of opposition or litigation; the patent remains active and enforceable in Finland.
Q3: Can this patent be applied outside Finland?
A3: Patent rights are territorial; to operate or enforce similar rights elsewhere, corresponding patents would need to be filed or validated in other jurisdictions.
Q4: How does this patent impact the development of new diagnostic devices?
A4: It provides a broad framework for designing devices that detect pharmacologically relevant features, encouraging innovation within its claims’ scope.
Q5: What future patent strategies should stakeholders consider based on this patent?
A5: Stakeholders should explore designing around the claims or focus on incremental innovations that improve detection sensitivity, portability, or data analysis to navigate around or build upon this patent.
References:
[1] Johnson, M., et al. (2004). "Electrochemical Biosensors for Pharmacogenomics." Analytical Chemistry.
[2] Lee, S., et al. (2008). "Nanomaterial-Enhanced Biosensors in Personalized Diagnostics." Biosensors & Bioelectronics.
